Ghazal Tansir | Oncology | Best Researcher Award

Published on by Global Academic Awards

Dr. Ghazal Tansir | Oncology | Best Researcher Award

All India Institute Of Medical Sciences Delhi | India

Dr. Ghazal Tansir, is an accomplished medical oncologist and researcher with a distinguished academic and clinical trajectory, holding an MBBS from Vardhman Mahavir Medical College, an MD in Internal Medicine from PGIMER, and a DM in Medical Oncology from AIIMS, New Delhi. She has served as Senior Resident and Research Consultant at AIIMS and is currently Assistant Professor at CAPFIMS-AIIMS, New Delhi. Dr. Tansir is an active member of the American Society of Clinical Oncology, European Society of Medical Oncology, and Indian Society of Medical and Pediatric Oncology. She has received multiple honors, including gold medals in Community Medicine and Ophthalmology, the AK Gadpayle Gold Medal in MD, selection for the ACORD protocol development workshop, the ASCO Merit Award, the ESMO Travel Grant, and the IDEA Award by Conquer Cancer. Her research contributions encompass over fifteen publications, focusing on rare cancers, sarcomas, and translational oncology, with studies on synovial sarcoma, mesenchymal chondrosarcoma, desmoid tumors, Li Fraumeni syndrome, and young-onset lung cancer. Dr. Ghazal Tansir has presented her work extensively at international conferences, including ASCO, ESMO, and the Connective Tissue Oncology Society, earning recognition for clinical and translational research excellence, making her a highly impactful researcher in medical oncology.

Profile: Google Scholar

Featured Publications

Tansir, G., Gupta, C., Mehta, S., Kumar, P., Soneja, M., & Biswas, A. (2017). Expanded dengue syndrome in secondary dengue infection: A case of biopsy proven rhabdomyolysis induced acute kidney injury with intracranial and intraorbital bleeds. Intractable & Rare Diseases Research, 6(4), 314–318.

Kumar, P., Tansir, G., Sasmal, G., Dixit, J., & Sahoo, R. (2016). Left pulmonary agenesis with right lung bronchiectasis in an adult. Journal of Clinical and Diagnostic Research: JCDR, 10(9), OD15.

Tansir, G., Kumar, P., Pius, A., Sunny, S. K., & Soneja, M. (2019). Pseudo-pseudo Meigs’ syndrome: A rare presentation of systemic lupus erythematosus. Reumatismo, 71(2), 108–112.

Biswas, S., Kumar, P., Tansir, G., & Biswas, A. (2019). Case report: Cardiac tamponade in dengue hemorrhagic fever: An unusual manifestation of a common disease. The American Journal of Tropical Medicine and Hygiene, 101(2), 448.

Tansir, G., Rastogi, N., Ramteke, P., Kumar, P., Soneja, M., Biswas, A., Kumar, S., & Jorwal, P. (2017). Disseminated mucormycosis: A sinister cause of neutropenic fever syndrome. Intractable & Rare Diseases Research, 6(4), 310–313.

Cheng Yi | Oncology | Best Researcher Award

Published on by Global Academic Awards

Mr. Cheng Yi | Oncology | Best Researcher Award

West China Hospital of Sichuan University | China

Mr. Cheng Yi, a distinguished Medical Doctor from Sichuan, currently serves as a professor and doctoral supervisor at the Cancer Center of West China Hospital, Sichuan University, and as an adjunct doctoral supervisor at Chengdu University of Traditional Chinese Medicine. He earned his Bachelor and Master of Medicine from Xi’an Jiaotong University, his Doctor of Medicine from Fudan University, and completed postdoctoral research at the University of Toronto. Since 1996, he has been deeply engaged in oncology clinical practice, scientific research, and teaching, advancing to professor and chief physician in 2006. His academic roles include standing committee and deputy director positions across multiple Chinese medical associations, reflecting his leadership in oncology and integrative medicine. With 138 publications, over 2,422 citations, and an h-index of 26, his research spans nanomedicine, cancer therapeutics, molecular oncology, immunotherapy, and systematic reviews, with impactful studies published in Journal of Materials Chemistry B, Nano Research, Frontiers in Oncology, PLoS One, and Journal of Cancer Research and Clinical Oncology. His international experience and consistent contributions to cancer treatment innovation highlight his strong candidacy for the Best Researcher Award, showcasing excellence in scientific impact, academic mentorship, and translational oncology research.

Profile: Scopus | Orcid

Featured Publications

Zhang, L.-N., Wei, Y.-F., Ran, X.-Y., Shi, L., Wang, Z.-Y., Chen, S.-Y., Yi, C., Yu, X.-Q., & Li, K. (2025). Liberating exciton transfer as a pioneering strategy to construct type I photosensitizers for hypoxia deep-seated metastases suppression. JACS Au. Advance online publication.

Tan, S., Feng, M., Zhou, N., Zhang, S., Yi, C., & Gou, H. (2025). DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer. Cancer. Advance online publication.

Chen, P., Hou, W., Li, C., Liang, Q., Ma, L., Zhao, X., & Yi, C. (2025). Lived experiences of patients with advanced pancreatic cancer on patient-reported outcomes (PROs) management: A qualitative phenomenological study in Southwest China. BMJ Open, 15(1), e084259.

Ran, X.-Y., Xia, W.-L., Zhang, L.-N., Yu, X.-Q., Chen, P., Xie, K.-P., Zhao, Y., Yi, C., & Li, K. (2024). De novo design of type-I photosensitizer agents based on structure-inherent low triplet energy for hypoxia photodynamic therapy. Materials Horizons. Advance online publication.

Tan, S., Zhang, S., Zhou, N., Cai, X., Yi, C., & Gou, H. (2023). Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study. Cancer Medicine, 13(1), e6786.

Wei, Y., Zheng, L., Yang, X., Luo, Y., Yi, C., & Gou, H. (2023). Identification of immune subtypes and candidate mRNA vaccine antigens in small cell lung cancer. The Oncologist, 28(11), oyad193.

Ashiq Ali | Oncology | Best Researcher Award

Published on by Global Academic Awards

Dr. Ashiq Ali | Oncology | Best Researcher Award

Dr. Ashiq Ali, Shantou University Medical College, China

Dr. Ashiq Ali is a dedicated postdoctoral fellow at Shantou University Medical College, China, with a strong academic background in Pathology and Immunology. He earned his Ph.D. in Pathology and Immunology from the University of Agriculture Faisalabad. With expertise in cancer epigenetics, immunoproteomics, and molecular diagnostics, he has significantly contributed to vaccine development and probiotic research. His commitment to advancing scientific knowledge is evident through numerous publications and successful research projects. As a passionate educator, Dr. Ali has experience mentoring students and conducting lectures on pathology and clinical diagnostics. His dedication to innovative research and academic excellence makes him a valuable contributor to the global scientific community. 📚🔬🧬

Publication Profile

Google Scholar

Education 🎓

Dr. Ashiq Ali pursued his Ph.D. in Pathology and Immunology (2017–2022) from the University of Agriculture Faisalabad, focusing on cancer epigenetics and immunoproteomics. Prior to that, he completed his M.Phil. in Pathology (2014–2016) at the same university, excelling in clinical diagnostics and molecular biology. His academic journey began with a Doctor of Veterinary Medicine (DVM) (2009–2014), where he developed a strong foundation in veterinary pathology, microbiology, and immunology. Throughout his education, Dr. Ali demonstrated exceptional dedication, earning prestigious scholarships and excelling in his research pursuits. His continuous pursuit of knowledge in pathological research and immunological studies highlights his commitment to contributing to the medical and scientific fields. 📘🧑‍🔬🔎

Experience 💼

Dr. Ashiq Ali is currently a postdoctoral fellow at Shantou University Medical College, China, conducting advanced research in pathology and immunology. From 2018 to 2019, he served as a Teaching Assistant at the University of Agriculture Faisalabad, where he conducted practical and theoretical classes on subjects like General Pathology, Clinical Pathology, and Oncology. Between 2016 and 2020, he contributed as a volunteer research assistant, gaining extensive hands-on experience in molecular diagnostics, PCR, immunohistochemistry, and virus cultivation. His role involved supervising laboratory operations, mentoring students, and conducting detailed investigations into infectious diseases, cancer research, and vaccine development. Dr. Ali’s dynamic experience across teaching, research, and lab management highlights his versatility and dedication to scientific advancements. 🧪🔎📊

Awards and Honors 🏆

Dr. Ashiq Ali’s academic excellence has been recognized through prestigious awards, including a Merit Scholarship during his M.Phil. in Pathology at the University of Agriculture Faisalabad (2014–2016). His exceptional research capabilities earned him the Indigenous Ph.D. Fellowship from the Higher Education Commission (HEC) of Pakistan (2018–2022), supporting his groundbreaking work in cancer epigenetics and immunology. These accolades underscore his academic dedication, research competence, and commitment to scientific growth. His contributions have not only elevated his academic standing but also significantly advanced the field of pathology and immunology. 🏅📚🧑‍🔬

Research Focus 🧬

Dr. Ashiq Ali’s research centers on cancer epigenetics, immunoproteomics, and molecular diagnostics, with a keen interest in tumor identification, immunohistochemistry, and gene expression analysis. His expertise includes the development of vaccines using plant-based adjuvants, investigating the therapeutic potential of interferon-alpha against viruses, and applying probiotics for mycotoxin biodegradation. Additionally, Dr. Ali explores the role of pathological markers in disease diagnosis and studies the effects of environmental toxins. His research contributions, particularly in advancing molecular and cellular pathology, continue to pave the way for innovative treatments in infectious diseases, oncology, and veterinary medicine. 🧫🧪🧑‍🔬

Publication Top Notes

  • 📖 Microbial and enzymatic battle with food contaminant zearalenone (ZEN) – Cited by: 23 – Year: 2022

  • 📖 In-vitro assessment of a novel plant rhizobacterium, Citrobacter freundii, for degrading and biocontrol of food mycotoxin deoxynivalenol – Cited by: 21 – Year: 2023

  • 📖 Prevalence, molecular characterization and antibiogram study of Listeria monocytogenes isolated from raw milk and milk products – Cited by: 18 – Year: 2020

  • 📖 Probiotics: Helpful for the prevention of COVID-19? – Cited by: 17 – Year: 2020

  • 📖 Green nanotechnology mediated silver and iron oxide nanoparticles: Potential antimicrobials – Cited by: 15 – Year: 2022

  • 📖 Type I IFNs: a blessing in disguise or partner in crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-induced pathology and potential use of type I IFNs in synergism with IFN-γ – Cited by: 14 – Year: 2021

  • 📖 Potassium use efficiency of maize hybrids – Cited by: 12 – Year: 2012

  • 📖 Aflatoxins associated oxidative stress and immunological alterations are mitigated by dietary supplementation of Pichia kudriavzevii in broiler chicks – Cited by: 10 – Year: 2021

  • 📖 Reply Letter-COVID-19 (Novel Coronavirus 2019)-Recent trends – Cited by: 10 – Year: 2020

  • 📖 Potential therapeutic strategies to combat HCC – Cited by: 9 – Year: 2022

  • 📖 Role of Streptococci as etiological agents of dental caries – Cited by: 9 – Year: 2020

  • 📖 Pollen micromorphology among amaranthaceous species from desert rangeland – Cited by: 8 – Year: 2023

  • 📖 Impact of silver dopant on structural, optical and electrical properties of ZnO nanoparticles – Cited by: 8 – Year: 2019

  • 📖 The adverse effects of carbofuran are efficiently counteracted by the supplementation of star anise (Illicium verum) in broiler chicks – Cited by: 7 – Year: 2020

  • 📖 Mitigative Potential of Novel Lactobacillus plantarum TISTR 2076 against the Aflatoxins-Associated Oxidative Stress and Histopathological Alterations in Liver and Kidney of Broiler Chicks – Cited by: 6 – Year: 2022

Conclusion

Dr. Ashiq Ali’s strong academic background, extensive research experience, and high-impact contributions in pathology and immunology make him a strong candidate for the Best Researcher Award. His expertise in molecular diagnostics, vaccine development, and immunology, coupled with his teaching and mentoring skills, align well with the award’s criteria.

Nilank Shah MD | Medicine | Best Researcher Award

Published on by Global Academic Awards

Dr. Nilank Shah MD | Medicine | Best Researcher Award

Course Director and Professor, Touro College of Osteopathic Medicine, United States

An accomplished medical professional with extensive expertise in pharmacology and toxicology, this individual has dedicated their career to advancing medical education and research. They have held various prestigious positions, including Principal Investigator at TouroCOM, where they focus on organ preservation and therapeutic solutions. Their commitment to innovation in teaching methodologies and multidisciplinary research reflects a deep passion for both education and health science. 🌟

Publication Profile

Google Scholar

Education

Graduating with an MBBS from MPS Medical College & Hospital in India, they further specialized with an MD in Pharmacology and Applied Therapeutics from the same institution. Their academic journey continued with an MS in Pharmacology & Toxicology from Long Island University, USA, followed by a Post-Doctoral Fellowship in Physiology and Pharmacology at the State University of New York. Additionally, they completed certificate programs in Food & Nutrition and Nutrition & Care with first-class honors from Indira Gandhi National University. 🎓

Experience

With a robust background in both clinical practice and academia, this professional has successfully integrated teaching with research. They have developed special methodologies and new pedagogies that enhance the learning experience for students in health sciences. Their role as a Principal Investigator on multiple funded research projects at TouroCOM highlights their ability to lead impactful studies in the field. 💼

Research Focus

Their research primarily concentrates on organ preservation solutions and the therapeutic effectiveness of innovative oxygen carriers in cardiac care. This work exemplifies their commitment to advancing healthcare through rigorous scientific investigation, bridging clinical applications with cutting-edge research in pharmacology and toxicology. 🔬

Awards and Honors

This individual has received numerous accolades for their contributions to medical research and education, including several funded research grants as Principal Investigator. Their recognition underscores their role as a leader in the field and their dedication to improving health outcomes through science and education. 🏆

Publication Top Notes

“Organ Preservation Solution: A Multidisciplinary Approach” – Journal of Clinical Pharmacology (2023) Cited by 30 articles

“Therapeutic Effectiveness of OxyVita Hemoglobin Based Oxygen Carrier” – Cardiology Research (2022) Cited by 25 articles

“Advancements in Organ Transplantation: A Review” – American Journal of Transplantation (2021) Cited by 40 articles

“Innovative Teaching Methodologies in Medical Education” – Medical Education Online (2020) Cited by 15 articles

 

Ken Kato | Oncology Award | Excellence in Research

Published on by Global Academic Awards

Dr. Ken Kato | Oncology Award | Excellence in Research

Dr. Ken Kato, National Cancer Center Hospital, Japan

Dr. Ken Kato is a distinguished Japanese oncologist specializing in gastrointestinal and esophageal cancers. With a robust career at the National Cancer Center Hospital in Tokyo, he leads divisions in translational research and medical oncology 🏥. Holding both an M.D. and a Ph.D. from prestigious institutions 🎓, Dr. Kato has a notable presence in clinical and research domains, with expertise in molecular targets and immunotherapy for cancer 🧬. His extensive publications in top medical journals highlight his dedication to advancing cancer treatment 📚. Dr. Kato is also an active member of several professional societies worldwide 🌏.

Publication profile

Scopus

Education

Dr. Kato earned his Ph.D. from Kyushu University in 2001 and his M.D. in 1995. He graduated from the University of Occupational and Environmental Health in 1989 🎓.

Research Focus

Dr. Ken Kato is a leading researcher in gastrointestinal and esophageal cancers, focusing primarily on early detection, treatment, and the molecular mechanisms of these malignancies 🧬. His work includes innovative studies on serum microRNAs for early gastric cancer detection, biomarkers for chemotherapy response, and the genetic underpinnings of cancer resistance 📊. He has explored the efficacy of various chemotherapeutic combinations, such as S-1 plus cisplatin for HER2-positive gastric cancer, and has investigated the impact of gene mutations in treatment outcomes 🚑. Dr. Kato’s research aims to advance precision medicine in oncology, improving patient survival and treatment efficacy 🌟.

Publication Top Notes

  • A novel combination of serum microRNAs for the detection of early gastric cancer – Abe, S., Matsuzaki, J., Sudo, K., … Saito, Y., Ochiya, T. Gastroenterological Endoscopy, 2021, 63(6), pp. 1310 📅, Cited by: 0 🔍
  • ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy – Takahashi, T., Yamahsita, S., Matsuda, Y., … Nagino, M., Ushijima, T. Journal of Cancer Research and Clinical Oncology, 2015, 141(3), pp. 453–463 📅, Cited by: 21 📊
  • Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer – Honma, Y., Shimada, Y., Takashima, A., … Sekine, S., Kushima, R. International Journal of Clinical Oncology, 2014, 19(5), pp. 863–870 📅, Cited by: 3 📈
  • Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer – Takahashi, N., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. BMC Research Notes, 2014, 7(1), 271 📅, Cited by: 41 🔬
  • Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection – Shoji, H., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. Cancer Science, 2014, 105(8), pp. 1002–1007 📅, Cited by: 24 🧬
  • Combined Assessment of Endothelial Growth Factor Receptor Dual Color In Situ Hybridization and Immunohistochemistry with Downstream Gene Mutations in Prediction of Response to the Anti-EGFR Therapy for Patients with Metastatic Colorectal Cancer – Takahashi, N., Yamada, Y., Taniguchi, H., … Hamaguchi, T., Shimada, Y. Archives of Medical Research, 2014, 45(5), pp. 366–374 📅, Cited by: 7 🔍
  • A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI) – Kato, K., Muro, K., Ando, N., … Nagai, K., Kato, H. Esophagus, 2014, 11(3), pp. 183–188 📅, Cited by: 30 🩺
  • Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: Combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912 – Takashima, A., Boku, N., Kato, K., … Shimada, Y., Ohtsu, A. Gastric Cancer, 2014, 17(3), pp. 522–528 📅, Cited by: 26 📊
  • Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma – Hayashi, H., Arao, T., Matsumoto, K., … Nishio, K., Yamada, Y. Oncotarget, 2014, 5(9), pp. 2588–2595 📅, Cited by: 33 🧪
  • Feasibility of endoscopic mucosal resection as salvage treatment for patients with local failure after definitive chemoradiotherapy for stage IB, II, and III esophageal squamous cell cancer – Makazu, M., Kato, K., Takisawa, H., … Yamada, Y., Shimada, Y. Diseases of the Esophagus, 2014, 27(1), pp. 42–49 📅, Cited by: 31 🩹